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Abstract

AMPK ACTIVATORS REGULATE CONTRACTILE FUNCTION OF MESENTERIC
ARTERIES

By Victoria April Locke, B.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

Virginia Commonwealth University, 2014

Director: Paul H. Ratz, Ph.D.
Professor, Department of Biochemistry & Molecular Biology and Pediatrics

Vasoconstrictor tone in the splanchnic circulation redistributes blood flow during
hemorrhage and resuscitation. A metabolic sensor, 5’adenosine monophosphate-activated protein
kinase (AMPK), has been proposed to relax arteries by inhibiting myosin light chain (MLC)
kinase (MLCK) and rho kinase (ROCK) activities. Because AMPK activation might be
beneficial in re-establishing splanchnic blood flow during resuscitation, we sought to explore the

viii

relative ability of AMPK activators (AICAR, A769662, berberine (BBR) and simvastatin
(SIMV)) to relax mesenteric artery (MA) contraction. Our data revealed that these drugs caused
vasorelaxation when tissues were stimulated either with KCl (producing primarily a Ca2+
dependent contraction) or phenylephrine (PE; producing a primarily Ca2+ independent
contraction). We further investigated the potential mechanisms by which BBR induced
mesenteric artery relaxation. We found that BBR did not inhibit MLC phosphorylation, nor did it
phosphorylate AMPK, and therefore is likely working through another mechanism to cause
vasorelaxation. Notably, PE induced an increase in AMPK phosphorylation and, of all the
AMPK activators examined, only AICAR phosphorylated AMPK in rabbit mesenteric artery,
which provides a guide for future studies.

ix

INTRODUCTION

1.1 Hemorrhagic Shock
Hemorrhagic shock (Figure 1) is initiated by rapid loss of blood volume, which decreases
cardiac output (CO) (amount of blood pumped from the heart to the organs), blood pressure
(BP) and blood flow to the organs. This reduced blood flow decreases the delivery of
nutrients and oxygen to the tissues. When blood pressure begins to drop, the initial
compensatory response from sympathetic autonomous nervous system outflow is to increase
venous constriction, heart rate, contractility and vasoconstrictor tone in “non-essential”
vascular beds, resulting in increases in total peripheral resistance (TPR), and a reduction in
the degree by which CO and BP fall. Norepinephrine released by sympathetic nerves that
innervate peripheral beds cause vascular smooth muscle contraction through activation of
alpha-adrenergic receptors. Because BP = CO X TPR, the increase in TPR helps to maintain
BP ensuring that brain and heart perfusion remain above the critical level needed for
survival, but at the cost of under perfusion of vascular beds that have been constricted. When
oxygen extraction is maximum at peripheral tissues, further decreases in oxygen supply to
these tissues can cause ischemia, even though the heart and brain are sufficiently perfused.
This can lead to minimal nutrients and oxygen at the peripheral tissues with an increase in
oxygen and nutrient demand. (Angele Martin. et al, 2008; Gutierrez G. et al 2004; Guyton
and Hall; Suarez RK. et al, 2004).
One method to improve the outcome of shock would be to decrease the energy demand at
peripheral tissues (including vascular smooth muscle) and enhance vasodilatation during
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reperfusion. There is evidence that increases in cellular AMPK activation could induce these
changes. However, it remains to be determined whether AMPK, which is activated during
states of metabolic stress, can be activated in mesenteric arterial vascular smooth muscle,
and whether such activation can cause inhibition of contraction, and thus, vasodilation, in this
artery to improve the outcome of hemorrhagic shock.
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(Angele, Martin, et al. “Bench to Bedside Review: Latest Results in Hemorrhagic Shock.” Crit Care. 2008)

Figure 1: A basic understanding of hemorrhagic shock. A decrease in systemic pressure
results in activation of the sympathetic nervous system; which causes vasoconstriction with a
decrease in oxygen delivery. This leads to a decrease in oxygen and nutrients that are
available for peripheral organs, with an increased demand, which can lead to multiple organ
failure. Additional deleterious effects include excessive immune system activation and
coagulopathy.
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1.2 Mesenteric Arteries and Blood Pressure Regulation
The mesenteric organs comprise about 5% of body mass, but receive about 30% of blood
flow distributed from cardiac output. The mesenteric arteries (Figure 2) are composed of
“arcades” or branching arteries from the main mesenteric artery. Primary branches are the first
branches off of the mesenteric artery. Secondary branches branch off of the primary, and so on,
with quaternary branches wrapping around the intestine itself to supply the intestinal tissues
directly.
Mesenteric arteries with diameters ~100-300 m in diameter display what is known as a
myogenic response which has been well described by many researchers (Baylis, WM 1902;
Christensen, 2001; Mulvany MJ, 1994; Mulvany MJ, 1990). The myogenic response causes a
vessel to constrict in response to an increase in blood pressure. The myogenic response is
thought to be a mechanosensor because it senses wall tension, which will induce the constriction
of the vessel (Johnson, 1980; VanBavel and Mulvany, 1994).
Studies have shown that these resistance arteries are more sensitive to muscle stretch in
vitro on a pressure myograph compared to an isometric myograph. A pressure myograph can
more appropriately model the in vivo condition (Halpern & Osol, 1985). Vessels that are
cannulated on a pressure myograph prove to be 5-10 fold more sensitive to muscle stretch
compared to vessels that are hung between clips on an isometric myograph. Thus, myogenic
contractions are studied using the pressure myograph system rather than the isometric ring
myograph preparation (Buus, 1994; VanBavel & Mulvany, 1994).
This response, in what are known as small muscular arteries and resistance arterioles, is
thought to play an important role in regulation of blood pressure and blood flow (Alemany CA,
4

1997; Myers SI, 1996; Nilsson C, 2001; Reilly P, 2001). As pressure falls in these arteries, the
flow is redistributed to different layers of the gastrointestinal tract (“gut”) and oxygen extraction
is increased until the flow falls below a critical level causing tissue injury (Reilly P, 2001).
Of interest to us is how the splanchnic circulation is affected during hemorrhagic shock.
The mesenteric circulation contains about 30% of the total circulating blood volume and has a
significant impact on both the gut itself and the outcome of the individual which makes the gut a
target for injury during shock and resuscitation. During severe hemorrhage, a disproportionate
increase in resistance in the mesenteric arteries leads to a decrease in mesenteric perfusion. This
decrease in perfusion causes a decrease in oxygen and nutrient supply and ischemia can occur,
which can affect other organs. This vasoconstrictor response is one of the basic mechanisms by
which blood pressure is maintained, with nearly 40% of the increase in TPR being in the
mesenteric vasculature. Also, gut venoconstriction can compensate for the decreased venous
return and therefor cardiac preload (filling pressure), which can return CO toward normal values.
Increases in TPR and CO can lead to diminished reductions in BP, but at the expense of gut
perfusion (Reilly, P. et al 2001).
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(http://www.daviddarling.info/encyclopedia/S/superior_mesenteric_artery.html)

Figure 2: Mesenteric artery arcades. The first branches off of the superior mesenteric artery are
primary branches. Branches off of the primaries are secondary and so forth. The arteries that
supply the gut directly are quaternary branches. The myogenic response is seen in arteries ~100300 m in diameter, usually secondary or tertiary branches, depending on the size of the
organism.
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1.3 5’Adenosine Monophosphate-Activated Protein Kinase (AMPK)
1.3.1 Structure and Function
AMPK is heterotrimeric serine-threonine protein kinase. Figure 3A shows that the complex
is composed of 1 catalytic  subunit, and 2 regulatory subunits (and ). The AMPK subunits
are composed of 7 genes (1, 2, 1, 2, 1, 2, 3) which make 12 possible heterotrimers. Of
importance is the catalytic subunit which contains threonine 172 (T172) that can be reversibly
phosphorylated (Fig 3A). AMPK is a metabolic sensing protein that is regulated by many
conditions such as exercise, hypoxia, ischemia, oxidative stress, and nutrient deprivation, but can
also be activated by pharmacological means. When phosphorylated at T172, AMPK becomes
activated and inhibits pathways that utilize energy and “turns on” pathways that produce energy
(Sanchez AM, 2012; Steinberg GR, 2009; Cheung PC, 2000; Stapleton D, 1996; Thornton C,
1998; Hardie DG, 1996).
Figure 3B shows the regulation and activation of AMPK. When inactive, the subunit of
AMPK is myristoylated and associates with the subunit of AMPK to create an inactivation
loop. Thesubunits are responsible for binding adenosine monophosphate (AMP) during times
of metabolic stress to allow the inactivation loop to open, which in turn will allow the catalytic
subunit to become phosphorylated at T172 (Fig 3B). Once this inactivation loop is opened, AMP
can bind to the  subunits and upstream kinases or pharmacologic activators can phosphorylate
T172. The binding of AMP to the  subunits prevents dephosphorylation of the T172 until ATP
levels are restored to normal levels (Cardaci S, 2012; Hardie DG, 2012; Stein SC, 2000).
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A.

B.

A. (Sanchez, A et al. “The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and
energy homeostasis.” American Journal of Physiology. 2012)
B. (Cardaci, S. “Redox Implications of AMPK-mediated signal transduction beyond energetic clues.” J Cell Sci.
2012.)

Figure 3: A) Schematic of AMPK structure and subunits.  catalytic subunit with a threonine
residue that is important for phosphorylation to activated the protein.  and  regulatory subunits.
B) Regulation of AMPK. A: AMPK  and  subunits are bound together and protein is inactive.
B: during metabolic stress, these subunits disassociate from one another and open the T172 site.
C: AMP inhibits dephosphorylation until ATP levels are restored.
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AMPK has become a protein of interest in vascular smooth muscle regulation. Vascular
smooth muscle expresses the 1 and 2 subunits, but the ratio of expression is vessel dependent
(Evans et al. 2006; Rubin et al, 2005). AMPK has been shown to cause vasodilation in vascular
smooth muscle through endothelium dependent and independent mechanisms (Goirand F et al,
2007). AMPK has two proposed mechanisms for regulating vascular smooth muscle: inhibiting
myosin light chain kinase (MLCK) and through inhibition of GTP-bound rhoA.
MLCK is responsible for phosphorylating MLC to promote tension development in
vascular smooth muscle. Horman et al (2008) has provided evidence that AMPK can directly
phosphorylate and desensitize smooth muscle MLCK at serine 815. This shows that vessels that
do not have functional endothelium present, AMPK can still regulate smooth muscle and allow
vasodilation by phosphorylating MLCK and decreasing its affinity for Ca2+-calmodulin. This is
not yet well understood, as this is the only paper that has been published showing that AMPK
can regulate smooth muscle through this mechanism.
RhoA is a G protein that cycles through states of GTP bound and GDP bound due to
intrinsic GTPase activity and GTP-GDP exchange (Puetz S, 2009). RhoA is regulated by
guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) which,
respectively, enhance nucleotide exchange and accelerated the intrinsic GTPase activity (see fig
5). G protein coupled receptors (GPCRs) that are activated by stimulants such as phenylephrine
can promote the GTP bound state of rhoA. Wang et al, (2011) has shown that activation of
AMPK promotes the GDP bound state of rhoA, which inactivates ROCK, which would allow
dephosphorylation of MLC20P by MLC phosphatase (MLCP). Again, this is not well understood,
as this is the only paper that has been publishing showing these results.
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Because of these two papers, it became of interest to us if activation of AMPK could help
promote vasodilation in peripheral tissues that have become constricted during hemorrhage, and
if AMPK could possibly help to prevent ischemic tissue damage due to constricted mesenteric
vasculature during hemorrhagic shock.

1.3.2 AMPK Activators
AMPK has many proposed pharmaceutical activators. Of these, two classes were chosen
for use in our studies: Known AMPK activators (AICAR, A769662) and drugs that are thought
to activate AMPK but that also have other cellular effects (berberine, simvastatin). Berberine is a
“nutriceutical” and simvastatin is a therapeutic agent used to reduce cholesterol levels. If these
agents act to induce mesenteric artery dilation due to activation of AMPK, then they could
potentially be repurposed as AMPK activators.
A) Known AMPK Activators:
AICAR: AICAR (acadesine) is an adenosine analog that is phosphorylated by adenosine
kinase to ZMP which mimics the effects of AMP on the subunits of AMPK to activate it
(Hardie DG, 2012; Steinberg GR, 2009). AICAR has been shown to have hypotensive effects in
vivo to cause vasorelaxation in arteries (Ford RJ, 2012). Studies have shown that administration
of AICAR to arteries in vitro has a direct vasorelaxation effect. Because AICAR is used to
mimic AMP that is present in near millimolar (mM) concentrations in cells, AICAR is effective
when used only in the mM range of concentrations (Goirand F, 2007).
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A769662: is a thienopyridone compound generated by Abbott Laboratories that causes
allosteric activation of AMPK. A769662 prevents dephosphorylation of AMPK at T172 but
phosphorylation of Ser-108 in the 1 subunit is required for stability. A769662 also allosterically
activates AMPK in the  subunits by mimicking AMP and preventing activation of AMP present
in the environment (Hardie DG, 2012; Sanders MJ, 2007; Steinberg GR, 2009).

B) Repurposed for AMPK Activation
Berberine (BBR): Berberine is an alkaloid derived from an herb used in traditional
Chinese medicine. Berberine has been shown to lower blood pressure in vivo (Sabir and Bhide,
1971) and to cause relaxation in isolated vessels in vitro (Chiou et al, 1991). Other studies have
shown that berberine reduced responses to phenylephrine in isolated preparations. Because of its
vasodilatory properties, it has been proposed that BBR may activate AMPK.
Simvastatin (SIMV): Simvastatin is an anti-cholesterol drug that blocks HMG-CoA
reductase. Previous studies have shown that statins can increase nitric oxide bioavailability and
other studies have shown that statins can phosphorylate AMPK in cultured cells (Sun W, 2006).
Rossoni et al (2011) has shown that SIMV can regulate contraction in arteries through a nitric
oxide dependent mechanism that also shows phosphorylation of AMPK.

1.4 Vascular Smooth Muscle Biochemistry
Although located in vastly different organ types, cardiac, skeletal and smooth muscle all
contract to generate tension in a relatively similar manner. Each of these muscle types is a chemo
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mechanical transducer that converts adenosine triphosphate (ATP) hydrolysis into acto-myosin
cross-bridge cycling leading to muscle contraction. Although these muscles generate tension
with the same molecular motor proteins, smooth muscle is unique compared to striated muscles
in the manner by which motor proteins are regulated.

1.4.1 Background and Latch Theory
Hollow organs such as the vasculature, urinary bladder, gastrointestinal tract, airways and
uterus all are lined with smooth muscle cells. Smooth muscle cells work together in a uniform
mechanism to develop force, which will help provide a motile force (intestines) or to alter the
dimensions of the organ that they are located in (urinary bladder). In regard to the different
demands of each part of the body, smooth muscle has two different types of force that can be
generated: tonic force and phasic force. Tonic smooth muscle cells generate a graded
depolarization, which in turn, generates a sustained contraction for long periods of time. This can
allow the tissues to tolerate loads that are imposed on them for long amounts of time without
fatigue or decline in force. Phasic smooth muscle cells generate action potentials, which
generates a quick “spike” of tension, followed by a falling off of force. This is generally
understood as peristalsis, meaning that these tissues cycle through phases of relaxation and
contraction. (Somlyo & Somlyo, 1994).
Tonic force can be maintained for long periods of time due to a highly efficient and
developed use of ATP. Although the detailed mechanism is not completely understood, a model
(Figure 4) was proposed by Hai and Murphy (1988) and Ratz, Hai et al (1989). A latch-bridge,
where high force (steady state) is maintained with low ATP use, is when attached cross bridges
become dephosphorylated, and these cross bridges become unattached at a much slower rate than
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those that are phosphorylated (“reduced levels of cross-bridge cycling”). The term latch-bridge,
which describes a dephosphorylated cross bridge that slowly becomes unattached was termed by
Dillon, Aksoy et al. in 1981. This model has been supported with evidence that shows that these
latch-bridges release ADP (Somlyo, Khromov et al. 2004). More recent evidence suggests that
the latch bridge model may act in tonic arteries more so than arteries considered to contract in a
phasic fashion, where tonic force maintenance is lower than the early phasic phase of tension
development. For example, whereas the muscular femoral artery undergoes “latch”, the
saphenous artery of rabbit, a branch of the femoral artery and “feed artery” for small muscular
arteries of the lower leg, does not enter the “latch” state. Thus, regulation of vascular smooth
muscle may be different in different vasculatures and in different sections of the vascular tree.
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(Hai and Murphy, “Cross-Bridge Phosphorylation and Regulation of Latch State in Smooth Muscle” American Phys
Society. 1988).

Figure 4: Hai and Murphy’s model of the latch theory. Calcium dependent smooth muscle
activation. A is actin, M is myosin, Mp is myosin that is phosphorylated but detached, AM is
actin-myosin complex, and Amp is actin-myosin complex that is phosphorylated.
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Smooth muscle is also unique from other muscle types because it does not contain
troponin. In cardiac and skeletal smooth muscle, Ca2+ binds directly to troponin, which causes a
conformational change in thin filaments, allowing myosin and actin to associate with each other.
In smooth muscle, although troponin is not present, binding sites on actin may be blocked
by other thin filament proteins such as calponin and caldesmon (Earley, Su et al,1998; Gusev,
2001). Ca2+ binds to calmodulin, which then will associate with MLCK to cause activation and
phosphorylation on serine-19 of the 20 kDa myosin light chains (MLC20P) (Kamm and Stull,
1985). This is necessary for cross bridge cycling and force development in smooth muscle. When
Ca2+ declines, MLCK becomes inactivated and will allow MLC20P to become dephosphorylated
by MLCP. Therefore, the regulation of smooth muscle contraction is dependent upon the ratio of
phosphorylated to dephosphorylated MLC (Somlyo & Somlyo, 1994).

1.4.2 MLC Phosphorylation Ratio
Phosphorylation of MLC20 is regulated by two main proteins: MLCK and MLCP. MLCK
“turns on” the contracted state of acto-myosin cross bridge (Figure 5). MLCP can
dephosphorylate MLC20P and turn crossbridge cycling “off”, which promotes the relaxed state
(Kamm and Stull 1985; Somlyo, Wu et al. 1999). Thus, it is the MLCK/MLCP ratio that is
important for regulation of smooth muscle contraction.

1.4.3 Calcium Dependent Regulation
Calcium (Ca2+) is vital for contraction in all muscle types even though there are
different effectors in the different types of muscle. The study of Ca2+ in regulation of smooth
muscle physiology has been critical to understanding the regulation of vascular smooth muscle
(Morgan and Morgan 1982; van Breemen, Chen et al. 1995; Karaki 2004). MLCK in smooth
15

muscle is activated by increases in intracellular free calcium ([Ca2+]i) and therefore, Ca2+ is noted
as an essential regulator of smooth muscle contraction (Figure 5, left side) (Kamm and Stull
1985).
Plasma membrane depolarization use high levels of extracellular potassium (KCl)
causes Ca2+ entry and, in some cells, Ca2+ release from intracellular stores, which will lead to
elevations in [Ca2+]I, activating Ca2+-calmodulin-dependent MLCK to cause contraction (Cool B,
2006; Kamm and Stull 1985). Thus, KCl acts through a non-receptor mediated mechanism to
bypasses plasma membrane GPCRs and cause increases in MLC20P and contraction (Cool, B.
2006).
AMPK has one proposed mechanism to regulate vascular smooth muscle through
a Ca2+ independent mechanism (Figure 5). Horman et al (2008) has proposed that AMPK
phosphorylates smooth muscle myosin light chain kinase (MLCK) and reduces its sensitivity to
calmodulin, which decreases the amount of phosphorylated MLC (Figure 5).

1.4.4 Calcium Independent Regulation
Studies in the early 1980’s began to recognize that smooth muscle activation
through GPCRs can produce increases in tension for a given increase in Ca2+ compared to
activation by membrane depolarization (KCl) (Morgan and Morgan, 1984). MLCP activity is
regulated by GPCR activation, and the activation of G-proteins creates second messengers which
inhibit MLCP (Somlyo, 2003). The upstream signals that are created through GPCR stimulation
are regulated at the plasma membrane even though the motor proteins are in the cell interior
(Ratz, 2005) (Figure 5, right).
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GPCRs can be activated by many stimulants, and once activated, can turn on guanine
exchange factors (GEFs) to promote the rhoA-GTP bound state. This activation promotes
activation of Rho Kinase (ROCK), which can inhibit MLCP to prevent dephosphorylation of
MLC20P. MLCP has three subunits, a 37 kDa catalytic subunit (protein phosphatase class 1, PP1c) which dephosphorylates MLC (Gong MC, 1992). The catalytic subunit is targeted to substrate
by myosin phosphatase targeting subunit (MYPT), which is 110-120 kDa. The last subunit is a
21 kDa M20 subunit (Johnson, Cohen et al. 1997), which binds to MYPT but has no known
function (Hartshorne, Ito et al. 1998). MYPT has two phosphorylation sites of interest, Thr853
(T853) and Thr696 (T696). The T853 phosphorylation site is the myosin regulatory binding site;
when phosphorylated, MLCP cannot bind to MLC20P to cause dephosphorylation, which would
allow tension to occur. The T696 phosphorylation site is the MYPT inhibitory site. When
phosphorylated at T696, MYPT becomes inactivated, and MLCP “turns off”, preventing
dephosphorylation of MLC20P (Hartshorne Ito et al, 2004).
AMPK has another proposed mechanism through the Ca2+ independent mechanism of
contraction. AMPK is proposed to promote the GTPase activating proteins (GAPs) which
promote hydrolysis of rhoA-GTP to the GDP bound state, which inactivates the protein. This
mechanism would reduce the level of active rhoA (the rhoA-GTP bound state), which would
reduce ROCK activity and, in turn, would allow MLCP to “turn on” and dephosphorylate
MLC20P.
AMPK has been shown to be a player in vascular smooth muscle regulation. We propose
that AMPK could play a vital role in the regulation of the vasculature during hemorrhagic shock,
and could help to extend survival by enhancing vasodilatation during resuscitation. It is
important to note that AMPK can mediate vascular smooth muscle regulation through
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endothelium dependent and independent mechanisms. Because the endothelium can become
damaged during hemorrhage, all of our experiments use mechanical and chemical removal of the
endothelium. The endothelium was removed chemically through the use of L-NMMA and ODQ.
L-NMMA blocks nitric oxide synthase (NOS), to prevent production of nitric oxide. ODQ
blocks soluble guanylyl cyclase which is a receptor for nitric oxide (NO). (Pinto, R. 2002).

Figure 5: A schematic of vascular smooth muscle regulation. Smooth muscle is regulated
through two main mechanisms: Ca2+ dependent (left side) and Ca2+ independent (right side).
AMPK has two proposed mechanisms: reducing MLCK activity and activation of rhoA-GAP to
inhibit active rhoA, and therefore, reduce ROCK activity.
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1.5 Objective
As mentioned, hemorrhagic shock is a complex injury involving decreased peripheral
tissue perfusion resulting in an increased need for oxygen by that tissue. AMPK is proposed to
cause vasorelaxation through two mechanisms: inhibition of MLCK and promotion of rhoAGAP. There are several drugs which are proposed to activate AMPK and cause vasorelaxation
through AMPK-dependent inhibition of MLC20P. This vasodilatory response could help provide
oxygen and nutrients to the peripheral tissues, which could prolong survival during hemorrhagic
shock. Therefore, the objective of this project was to test the hypothesis that certain compounds
known to activate AMPK can cause vasodilation in mesenteric arteries, to determine whether
these compounds activate AMPK, and specifically to examine the mechanism by which one of
these compounds, BBR, causes vasodilation of mesenteric arteries.
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Methods and Materials

2.1 Tissue Preparation
All experiments with animals were conducted under the regulations and guidelines and
approved by the Virginia Commonwealth University Institutional Animal Care and Use
Committee. Male New Zealand White rabbits were anesthetized with a mixture of Ketamine
(Ketaject®, Phoenix) and Xylazine (Anased ®) and euthanized with an overdose of pentobarbital
(Euthasol®, Virbac) for in vitro analysis. Mesenteric arteries (MA) were immediately collected
and placed in 4°C normal physiological saline solution (NPSS; in mM: 140 NaCl, 4.7 KCl, 2.0
morpholino-propanesulfonic acid (MOPS), 0.02 Na2ethylenediamine tetraacetic acid (EDTA),
1.2 Na2HP04•7H2O -to chelate trace heavy metals, adjusted to pH 7.4 with 5M NaOH at 37°C,
1.2 MgCl2, 1.6 CaCl2 and 5.6 α-D-glucose). The arteries were stored no longer than four days
covered at 4°C in NPSS.
Arteries were cleaned of surrounding fat, adventitia, and denuded of endothelium by
rubbing the intimal surface with a metal rod about the size of the arterial lumen diameter under a
binocular dissecting microscope to prevent damage (Olympus SZX12 or Zeiss 10093). The
blood contained within the lumen was blown out with a small syringe and the arteries were cut
into 3 mm-wide rings or a 6 mm long tube for isometric and isobaric analysis respectively.

2.2 Isometric Force Analysis
Contractile tension (T) was measured as previously described (Ratz, 1990). Following
tissue removal and cleaning to remove connective tissue and blood, each primary MA was cut
into several rings ~3mm in length and ~ 1mm in diameter. Each ring was hung between wire
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clips in a temperature controlled 6 mL tissue bath containing 37°C NPSS bubbled with air
(Myograph System-610M -Danish Myo Technology, Denmark: Figure 7A). Smaller secondary
arteries were prepared as previously mentioned. These arteries were cut into ~2mm lengths
(~450 m diameter) and hung between tungsten wires on a Mulvany clip wire myograph in a
temperature controlled 6 mL bath containing 37°C NPSS bubbled with air (Radnoti- Monrovia,
CA: Figure 7B). Both of these were connected to a transducer and a micrometer for force
measurements and length changes respectively. An analog-digital converter board (National
Instruments) collected the data and it was analyzed using DASYLab (DasyTech; Amherst, NH).
Voltage signals from the Myograph were digitized and visualized on a computer screen as F (in
grams).

2.2.1 Tissue Equilibration
The rings taken from the refrigerator were warmed for 15 minutes to 37°C in aerated
NPSS. The myograph system was then calibrated with the DASYLab software and DMT
calibration kit (Force Calibration Kit- Danish Myo Technology, Denmark).
The tissues were stretched to an initial 0.25 grams of force and allowed to stress- relax
for 3 minutes. MA was then contracted with a high potassium solution (KPSS; NPSS in which
110 mM KCl was substituted isosmotically for NaCl) for 3 to 5 minutes to initiate a contraction
and determine the viability of the tissues. The KPSS was washed out twice with NPSS and the
artery stress-relaxed for 10 minutes. The peak value over a 15 second interval of the KPSS
contraction was identified as the maximal tension (TT) at that length.
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2.2.2 L0 Determination
The muscle length (L0) that produced the maximum tension (To) was determined using an
abbreviated length-tension curve (Herlihy and Murphy 1973; Ratz and Murphy 1987). For MA,
the passive (TP) to active tension ratio (TA= (TT-TP/ TP) at L0 was 0.25 ± 0.03.
The tissue was prepared and equilibrated as previously mentioned. The peak value over a
15 second interval of the KPSS contraction was measured for the maximal force (TT). The
passive force (Tp) at that muscle length was the average pre-contractile tension. Following a
calculation of the tension ratio at L0 the artery was then stretched in increments of 0.25 grams
until a stress-relaxed value approximately twice the Tp was obtained. Each artery ring was
released quickly to their calculated passive tension (Tp), immediately contracted with KPSS for 5
minutes, and washed twice with NPSS. This procedure was repeated (usually twice) until the
muscle length was within the estimated L0 range for MA (Figure 6)
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Figure 6: MA at L0. The artery was stretched in increments of 0.5g (not shown) until a value
about 2x greater than the passive tension, Tp. The artery was then released to its calculated Tp
and contracted with KPSS to generate the active tension, Ta. These values allow us to calculate
the active to passive ratio, or the L0, which is the muscle length that generates the strongest
contraction. L0 for MA is 0.25.
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2.3 Isobaric Concentration Response Curve
Secondary MA was cleaned and prepared as previously mentioned. A ~6mm (~450 m
diameter) artery tube was hung between two glass cannula on a temperature controlled
pressurized myograph (110P Danish Myograph Technology, Denmark; Figure 7C), sutured at
each end with nylon suture provided by DMT, and immersed in 37°C NPSS bubbled with air.
The stage was connected to an inverted microscope (Zeiss) with a USB video camera connected
to a computer where the image was digitized and analyzed by MYOVIEW (DMT, Denmark) to
continuously record the outer diameter of the vessel and control the pressure and flow in the
artery. The artery was pressurized to 40 mmHg in a “no flow” system and was equilibrated in
37°C NPSS for 1 hour. KPSS was added for 3 minutes to determine viability of the tissue and
washed out twice with NPSS for a total of 10 minutes. The artery was pressurized to 80 mmHg,
the calculated mean arterial pressure for NZW rabbits (Call, 2006) and equilibrated for 15
minutes. 30 M ODQ and 100 M L-NMMA (O/L) were added for 15 minutes to block nitric
oxide synthase and cyclic guanine monophosphate (cGMP). After, the NPSS solution was
exchanged for KPSS + O/L for 3 minutes. The solution was washed out twice in the presence of
O/L and another contraction was initiated with 1 M phenylephrine (PE) for 3 minutes. This was
also washed out for a total of 10 minutes with NPSS + O/L. Vehicle, dimethyl sulfoxide
(DMSO) or drug (BBR) was added for 30 minutes in the presence of O/L. Increasing doses of PE
from 3E-8- 3E-5 M were added as the diameter stabilized from the previous dose added. At the
end of the experiment, the buffer was exchanged for 0 Ca2+ (NPSS, no calcium present), EGTA
(ethylene glycol tetraacetic acid) to chelate calcium, plus 10 M papaverine (a phosphodiesterase
inhibitor) buffer to measure the fully relaxed diameter of the vessel. Values were taken at a point
where the vessel diameter was relatively stable.
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2.4 Isometric Concentration Response Curves (CRC)
Secondary MA was cleaned and hung on a small vessel Mulvany clip wire myograph as
previously described. Values of 0.22 and 0.26 for the first and second L0 were used respectively.
After L0, the arteries stress relaxed in NPSS for 15 minutes. 30 M ODQ, 100 M L-NMMA and
1M Phentolamine were added to block nitric oxide synthase, cGMP and to block alphaadrenergic receptors. These were placed in the bath solution for 15 minutes and remained there
for the rest of the experiment. Vehicle (DMSO) or drug, (A76966, AICAR, BBR, SIMV at
different doses) were placed into each bath for 30 minutes to 2 hours (AICAR). Afterwards, each
artery was subjected to either a phenylephrine (PE, Calcium independent) concentration response
curve with increasing concentrations from 3x10-8 to 3x10-5 M (Figure 9) or a potassium chloride
(KCl, calcium dependent) (Figure 8) concentration response curve with increasing
concentrations from 10 mM to 60 mM. Each dose was mixed in each bath with a pipette to
ensure it was evenly dispersed throughout. Each dose of stimulant was added before the phasic
tension from the previous dose fell off. Values were obtained from the average of the peak
phasic tension over a 5-10 second time period.
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A.

C.

B.

http://www.dmt.dk/files/mounting_photos/pins_chamber_top2.jpg;
http://www.dmt.dk/files/mounting_photos/wire_mounted_top2.jpg

Figure 7: Vessel preparations used. A) Wire myograph system used to measure isometric
tension (~3mm length, ~1mm diameter). B) Mulvany Clip wire myograph used to measure
isometric tension (~2 mm length, 450 m diameter). C) Pressure/Diameter myograph used to
measure isobaric shortening (~6mm length, 450 m diameter).
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Figure 8: Secondary MA KCl dose response curve. Increasing doses are added from 10 mM to
60 mM before the tension from the previous contraction fell off.

Figure 9: Secondary MA PE dose response curve. Increasing doses are added from 0.03M to
30M before tension from the previous phasic portion of contraction fell off.
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2.5.1 Determination of Steady State
Primary MA was cleaned and prepared as previously mentioned above for isometric
analysis. Data was collected through DASYLab as noted above. An example of the protocol is
shown in Figure 10. After the arteries were at L0, they stress-relaxed in NPSS at 37°C for 15
minutes. After, ODQ and L-NMMA were added for another 15 minutes and remained in the bath
for the rest of the experiment. The first channel remained at basal level, and was quick frozen in 80°C TCA-acetone (Figure 10 A) (6% Trichloroacetic Acid (TCA), 10 mM dithiothreitol (DTT),
30 mM sodium fluoride (NaF) volumized with acetone). The last three baths were stimulated
with 10 M PE and quickly frozen in -80°C TCA-acetone at time points of 2, 30 and 60 minutes
post stimulation (Figure 10 B-D).
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Figure 10: Determination of MA Steady State. All arteries are in the presence of O/L A) MA
frozen at basal level. B) MA frozen 2 minutes post stimulation with PE. C) MA frozen 30
minutes post stimulation with PE. D) MA frozen 60 minutes post stimulation with PE
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2.5.2 30 M Berberine ± 10 M PE
A time point of 30 minutes was chosen from the control experiments because the force
remained at a pseudo-steady state after stimulation with PE. 4 MA were cleaned and prepared as
previously mentioned for isometric analysis. After the arteries were at L0, they relaxed in NPSS
at 37°C for 15 minutes, after which ODQ and L-NMMA were added for another 15 minutes and
remained in the baths for the rest of the experiment. The first and third artery baths contained
DMSO (vehicle) (Figure 11 A,B), while the second and fourth each contained 30 M BBR for
30 minutes. The last two baths were stimulated with 10 M PE for an additional 30 minutes
(Figure 11 C,D) while the first two baths remained at basal levels (Figure 11 A, B). All channels
were quick frozen in -80°C TCA–acetone at the end of the experiment.
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Figure 11: Rabbit mesenteric artery at L0. A. Basal with ODQ and L-NMMA, in the presence of
DMSO and frozen. B. Basal with ODQ and L-NMMA in the presence of 30 M BBR. C. DMSO
and ODQ and L-NMMA stimulated with 10M PE. D. 30 M BBR with ODQ and L-NMMA
stimulated with 10M PE.
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2.5.3 2 mM AICAR ± 10 M PE
A time point of 30 minutes was chosen from the control experiments because the force
remained at a pseudo-steady state 30 minutes after stimulation with PE. 4 MA were cleaned and
prepared as previously mentioned for isometric analysis. After the arteries were at L0, they
relaxed in NPSS at 37°C for 15 minutes, after which ODQ and L-NMMA were added for
another 15 minutes and remained in the baths for the rest of the experiment. The first and third
artery baths contained DMSO (vehicle) (Figure 12 A, B), while the second and fourth each
contained 2mM AICAR for 2 hours. The last two baths were stimulated with 10 M PE for an
additional 30 minutes (Figure 12 C, D) while the first two baths remained at basal levels. All
channels were quick frozen in -80°C TCA–acetone at the end of the experiment.
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Figure 12: Active tension of rabbit mesenteric artery at L0. A) Basal with O/L in the presence of
DMSO. B) Basal with O/L in the presence of 2mM AICAR. C) DMSO + O/L stimulated with 10
M PE for 30’. D) 2mM AICAR + O/L stimulated with 10M PE for 30’.
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2.5.4 Zero Load MA (Lz)
Primary MA was cleaned as previously mentioned and cut into 6 equal lengths ~ 5 m
long. The blood was blown out with a syringe and the endothelium was gently rubbed to remove
the endothelial cells. 8 total beakers were prepared. 2 NPSS and 1 KPSS beakers for
equilibration, and 6 test conditions: control (DMSO), STARVE (NPSS, no glucose, bubbled with
nitrogen, pO2 < 20 mmHg) 30 M A769662, 2 mM AICAR, M BBR and 30 M SIMV. 30
M ODQ and 100M L-NMMA were added to each of the test beakers. The arteries were
cleaned and placed into a NPSS beaker while bubbled with air. The arteries were not placed
under tension (i.e., they were at zero load, Lz) and were warmed to 37°C for 1 hour. After this,
and although the tissues were not externally loaded, they were transferred into KPSS for 3
minutes for equilibration, washed twice in NPSS for 10 minutes, transferred to KPSS for 5 more
minutes, and washed with NPSS for 15 minutes to simulate the protocol used for tissues that
were loaded to L0. ODQ and L-NMMA were added for 15 minutes. One artery was added to
each test condition (2 hours – AICAR, 1 hour – control, 30 minutes: A769662, BBR, SIMV,
STARVE). Each artery was frozen in TCA-acetone and warmed as previously mentioned. The
arteries were dried, weighed and assayed in a protein assay.

2.6 Homogenization
The tissues were warmed to room temperature in a chemical hood, washed twice in room
temperature acetone, dried by squeezing in filter paper, weighed in milligrams, and were
homogenized in homogenizing buffer (1% sodium dodecyl sulfate (SDS), 10% glycerol, 20 mM
DDT, 25 mM Tris-Base, bromophenol blue, 20 g/mL Leupeptin, 20 g/mL Aprotonin, 20
g/mL 4-Amidinophenylmethanesulfonyl fluoride hydrochloride (APMSF), 5 mM ethylene
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glycol tetraacetic acid (EGTA), 1 mM Ethylenediaminetetraacetic acid (EDTA), 50 mM sodium
fluoride (NaF), and 1 mM activated sodium orthovanadate) to a minimum final volume of 200
L (weight of tissue in mg/mL divided by protein in g/L). The samples were extracted
overnight in a 4°C refrigerator. The next day the samples were boiled for 10 minutes and
clarified by centrifugation for 10 minutes at 14,500 RPM. The supernatant was transferred into
clean tubes, and the pellet was thrown away. The samples were stored at -20°C.

2.7 Protein Assays
Thirteen % separating polyacrylamide gel with a 5% stacking polyacrylamide gel was
used in a 1.0 mm, 10 or 15 well gel plate (BioRad). Bovine serum albumin (BSA) diluted in
homogenizing buffer (0.2 mg/mL) was used for a protein standard and equivalent amounts of test
sample was added to each well, Precision Plus All Blue ™ (Biorad) protein marker in the last
well. SDS-PAGE was run at 190V for about 1 hour with running buffer (1.92 M glycine, 0.25M
Tris-Base, 1% sodium dodecylsulfate, volumized with deionized water, pH 8.3). Afterwards, the
gels were stained with Comassie Brilliant Blue overnight (25% ethanol, 10% acetic acid,
Coomassie brilliant blue, volumized with deionized water). The gels were then destained (Fast
Destain, 25% Ethanol, 10% Acetic Acid, volumized with deionized water) for about 2 hours,
scanned, and the actin bands of the samples were analyzed using ImageJ (nih.gov). The protein
concentration was determined using (actin/0.2) = amount of protein/L loaded. This value was
divided by the number of the desired amount of protein load (i.e. 5, 15, 20 g).

2.8 Western Blotting
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After protein assays were complete, the samples were available to be used in a western
blot. 10% acrylamide separating with 5% stacking gels were prepared. 5 L of Full-Range
Rainbow Molecular Weight Marker™ (GE Healthcare, Pittsburgh, PA) was used as a protein
ladder in the first lane and 5 L of an enhanced chemiluminescense (ECL) marker (Supersignal
Molecular Weight Ladder, Thermo Scientific) diluted 1/50 uL in 1D homogenizing buffer was
used as a protein ladder for ECL in the last lane. All lanes were loaded with their appropriate
amounts, and SDS-PAGE was run with running buffer at 190V for 1 hour or until the protein
bands were at the very bottom of the gel. During this time, polyvinylidene fluoride (Immobilon
PVDF, Millipore) membranes were prepared and stabilized in transblot buffer (0.189M Glycine,
0.0247 Tris-Base, 10% methanol, 0.02% SDS, volumized with deionized water). Western blots
were prepared in this order: sponge pad, filter paper, 2 PVDF membranes, gel, filter paper and
another sponge pad. The blots were built and placed into a western blotting apparatus (Biorad).
An ice pack (used as a heat sink) was placed in each blot box and filled with transblot buffer.
The blot tanks were submerged in a bucket of ice to keep the apparatus cool during the transfer.
Proteins were transferred for 1 hour at 110V or 1.5 hours at 100V (AMPKp). The second
membrane (not next to the gel) was stained with Colloidal Gold Total Protein Stain (Biorad) to
determine if the transfer was successful. Afterwards, the first membrane (next to the gel) was cut
along the marker lines for specific proteins of interest (AMPK- 72 kDa, B-actin- 42 kDa, MLCP20 kDa, MYPT- 130 kDa) and placed immediately in blocking solution for 1 hour or overnight.
Membranes were then washed three times 5 minutes in 1X TTBS (10 mM Tris-Base, 100M
NaCl, 0.1% Tween, pH 7.6 with hydrochloric acid) and primary antibody was added overnight.
The next day, the blots were washed again, and secondary antibody (goat anti-rabbit HRP, Santa
Cruz: Dallas, Texas) was added for the appropriate time. The blots were washed three more
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times with TTBS and 1 mL per membrane of enhanced electrochemiluminescence (ECL) was
added (Thermo Scientific, Waltham, Massachusettes) The blots were exposed to x-ray film
(Carestream Kodak, Rochester, NY) for an appropriate amount of time in a dark room and the
films were processed using a tabletop x-ray film processor in the dark room (Konica, Tokyo,
Japan). Western blot films were scanned, digitized, and analyzed through Image J.

2.8.1 5’ Adenosine Monophosphate Protein Kinase (AMPKp-T172):
15g of protein was loaded into each lane for AMPKp-T172 western blot analysis. After
transferring for 1.5 hours at 100 volts, blots were blocked in a solution 3% BSA in 1X TTBS
overnight at 4°C (to lower background signal). The next day, the membranes were washed for 5
minutes three times with TTBS. Primary antibody (monoclonal, anti-phospho-AMPK-T172, 72
kDa antibody produced in rabbit) from Cell Signal was used. This antibody was diluted 1:1000
in blocking solution and was incubated overnight at 4°C. The next day, the blots were washed
for 5 minutes three times. Secondary antibody (goat anti-rabbit HRP, Santa Cruz) diluted 1:5,000
in block was used for 1 hour while rocked at room temperature. The blots were then washed,
ECL was added, and they were exposed for 1-15 minutes in a dark room and processed. Because
they are close in molecular weight, blots were stripped (Restore Western Blot Stripping Buffer,
Pierce) for 15 minutes and washed 3 times 5 minutes with TTBS and reprobed for 1 hour for
beta-actin and completed as noted below.

2.8.2 eta –Actin:
Beta actin was used as a loading control. Blots were blocked in a solution 3% BSA in 1X
TTBS for 1 hour at room temperature. Then, the membranes were washed for 5 minutes three
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times with TTBS and stored overnight. Conjugated antibody (b-actin HRP (42 kDa), Santa Cruz)
was diluted 1:100,000 in block. The antibody was added for 1 hour. The blots were then washed,
ECL was added, and they were exposed for 5-15 seconds in a dark room and processed.

2.8.3 Myosin Light Chain20 Phosphorylation- Ser19 (MLC20P):
Blots were blocked in a solution of 0.5% blotto (dry milk) and 1.9% BSA in 1X TTBS
for 1 hour, while rocked at room temperature. The membranes were washed for 5 minutes three
times with TTBS. Primary antibody (monoclonal, anti-myosin light chain 20 kDa antibody
produced in mouse) from Sigma was used. This antibody was diluted 1:2500 in blocking solution
and was incubated overnight at 4°C. The next day the blots were washed for 5 minutes three
times. Secondary antibody (goat anti-rabbit HRP, Santa Cruz) diluted 1:5,000 in block was used
for 1 hour while rocked at room temperature. The blots were then washed, ECL was added, and
they were exposed for 10-15 seconds in a dark room and processed.

2.8.4 Myosin Phosphatase Targeting Protein (MYPT) – THR 850/696 (MYPT- T850/ 696):
Blots were blocked in a solution 3% blotto (dry milk) in 1X TTBS for 1 hour, while
rocked at room temperature. The membranes were washed for 5 minutes three times with
deionized water. Primary antibody (monoclonal, anti-phospho-MYPT1 (THR850) 130 kDa
antibody produced in mouse) from Upstate was used. This antibody was diluted 1:1000 in
blocking solution and was incubated overnight at 4°C. The next day, the blots were washed for 5
minutes three times. Secondary antibody (goat anti-rabbit HRP, Santa Cruz) diluted 1:5,000 in
block was used for 1.5 hours while rocked at room temperature. The blots were then washed,
ECL was added, and they were exposed for 10-15 seconds in a dark room and processed.
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The membranes were stripped (Restore Western Blot Stripping Buffer, Pierce) for 15
minutes and washed for 5 minutes three times with deionized water. Primary antibody
(monoclonal, anti-phospho-MYPT1 (THR696) 130 kDa antibody produced in mouse) from
Upstate was used. This antibody was diluted 1:10,000 in blocking solution and was incubated
overnight at 4°C. The next day, the blots were washed for 5 minutes three times. Secondary
antibody (goat anti-rabbit HRP, Santa Cruz) diluted 1:5,000 in block was used for 1.5 hours
while rocked at room temperature. The blots were then washed, ECL was added, and they were
exposed for 10-15 seconds in a dark room and processed.

2.8.5 Western Blot Data Analysis:
All western blot films were scanned and analyzed through Image J. Phosphorylation was
calculated by dividing the value over b-actin, and normalizing that value to the basal to make
control =1. All data was imported into Prism Graph pad 6.04.

2.9 Drugs:
2.9.1 AMPK Activators
A769662: Was purchased from LC Laboratories and dissolved in DMSO.
AICAR: Was purchased from LC Laboratories and dissolved in 37°C NPSS
Berberine (BBR): Was purchased from Cayman Chemical and dissolved in
dimethylsulfoxide (DMSO)
Simvastatin (SIMV): Was purchased from Cayman Chemical and dissolved in
DMSO
DMSO: was purchased from Fisher BioReagents and was used as a vehicle
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2.9.2 Nitric Oxide Inhibitors
L-NMMA: was purchased from Enzo and dissolved in deionized water
ODQ: was purchased from Alexis Chemical and dissolved in DMSO
Papaverine: was purchased from Sigma and dissolved in deionized water
2.9.3 Alpha- Adrenergic Receptor Regulators
Phentolamine (PT): was purchased from Sigma and dissolved in deionized water
Phenylephrine (PE): was purchased from Sigma and dissolved in deionized water

2.10 Statistics:
For each study, the n value was equal to the number of rabbits from which arteries were
taken. After normalization in Microsoft Excel (Microsoft Corporation, Redmond, WA), the raw
data was entered into Graph Pad Prism 6 (Graph pad Software, Inc., San Diego, CA) and
analyzed using the “Sigmoidal dose-response (variable slope)” equation: Y=Bottom + (Top –
Bottom)/(1+10^((LogEC50-X)*Hillslope)), where X is the logarithm of concentration, Y is the
response, Y starts at the Bottom and goes to the Top with a sigmoidal shape. Log EC50,
Hillslope, and maximum efficacy (top) were evaluated statistically. When two groups were
compared, a Student’s t-test was used and the null hypothesis was rejected at P <0.05. When a
group was compared twice, then the Bonferroni correction was used. Otherwise, the 1-way
ANOVA and Tukey post-hoc test was used. All concentration response curves were fitted to a
sigmoidal curve using Prism software (GraphPad Software Inc)
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RESULTS

3.1. AMPK Activators on KCl Concentration Response Curve
KCl elicits contraction through depolarization of the cell, which allows influx of
Ca2+ to initiate a contraction (tension). There are two phases of contraction in rabbit mesenteric
artery, an initial peak of tension (phasic phase) and a tonic phase that is not sustained, but is
reduced over time (tonic phase). This study was done by adding in 5 and 10 mM increments of
increasing concentrations of KCl from 10-60 mM before the phasic phase of tension fell off
towards the tonic phase. The purpose of this experiment was to see if these drugs can vasodilate
mesenteric artery by attenuating the Ca2+ dependent contraction pathway. Of interest was to
determine whether the AMPK activator reduced the maximum efficacy (maximum tension) and
the potency (the EC50). The data was collected by taking the average of the maximum tension
(peak or steady-state) over a 5-15 second interval of each contraction as described in the
methods.
In the presence of the vehicle for the drugs used, DMSO, the maximum KCl
concentration produced a maximum tension that was ~50% of the normalized maximum tension
produced by KCl during the L0 determination. This was anticipated because the KCl
concentration response curve experiments were performed by adding KCl in the presence of
phentolamine, an -adrenergic receptor antagonist which blocks the ability of norepinephrine
released by periarterial nerves to activate -adrenergic receptors that would, in turn, activate the
rhoA-GTP pathway. The KCl concentration-response curve data were presented as normalized
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to tension produced by KCl without the -adrenergic receptor blockade (1.0 T/T0). Thus, it can
be concluded that about 50% of a mesenteric artery contraction induced by KCl in the absence of
phentolamine (-adrenergic antagonist) was caused by the release of norepinephrine from
periarterial nerves and subsequent activation of vascular smooth muscle -adrenergic receptors.
AICAR (2 mM, 2 hours, Figure 13, A) caused a significant change in the EC50 (reduction
in the potency) of a KCl concentration response. The non-nucleotide AMPK activator, A769662
(Fig 13, B), had no effect on a KCl concentration response. 10 M BBR (Fig 13, C) had no
effect compared to the vehicle, but 30 M BBR (Fig 13, C) caused a depression in the efficacy
of the contraction. 10 M SIMV (Fig 13, D) caused a complete inhibition of KCl-induced
tension whereas 1 M SIMV depressed the efficacy of the contraction (Fig 13, D), but not as
strongly as 10M. These data support the hypothesis that 2mM AICAR, 30M BBR, and SIMV
(both concentrations) are effective vasodilators in rabbit mesenteric artery.
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Figure 13: Different hypothesized AMPK activators and their effects on KCl concentration
response curves in mesenteric arteries (MA). (A) 2mM AICAR and vehicle. AICAR produced a
significant change in the EC50. (B) AMPK activator A769662 and vehicle, A769662 had no
effect. (C) 10 and 30 M BBR and vehicle. 10 M had no effect while 30 M produced a
significant decrease in the efficacy (D) 1 and 10M SIMV and vehicle, 10 completely inhibited
while 1M was able to reduce tension.
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3.2. Effects of AMPK Activators on PE Concentration-Response Curve (CRC)
3.2.1 Isobaric Concentration Response Curve
Phenylephrine causes tension through activation of alpha-adrenergic receptors which
activate RhoA to the GTP bound state, which will turn on ROCK and block myosin phosphatase
to allow tension to build (Ca2+ independent). Previous studies have shown that pressurized
vessels are more sensitive to alpha-agonists (Mulvany, 1994). It is also thought that pressurized
preparations are more comparable to in vivo. This study used mesenteric arteries that were
pressurized to 80 mmHg in a “no flow” system.
Of interest to us was the effect of BBR in a pressurized vessel. Phenylephrine (PE), an
alpha adrenergic agonist, was used in increasing concentrations (0.03-30M) to cause
contraction in rabbit MA in the presence of ODQ, L-NMMA and vehicle or drug. 30 M BBR
reduced the sensitivity of the PE induced concentration response (Figure 14) but it did not
depress the maximum in the isobaric system. These data are comparable to the isometric studies
with 30 M BBR.
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Figure 14: Mesenteric artery pressurized at 80 mmHg. 30M BBR in the presence of ODQ and
L-NMMA. 30 M BBR was able to reduce the efficacy and potency of a PE CRC.
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3.2.1 Isometric Concentration Response Curves (CRC)
Phenylephrine elicits tension through a Ca2+ independent pathway, and therefore the
purpose of this study was to determine if the AMPK activators cause vasorelaxation through a
Ca2+ independent pathway.
2mM AICAR (Fig 15, A) did not have any effect on a PE-induced CRC, which was
different from a KCl CRC. A769662 (Fig 15, B) significantly (P <0.05) decreased the potency
and changed the EC50 and hill slope of a PE CRC. m BBR (Figure 15, C) significantly (P
<0.05) decreased the potency. 30 m SIMV significantly (P < 0.05) decreased the efficacy of the
response, where 10m may have an effect but 1m SIMV had no effect (Figure 15, D). These
data conclude that A769662, BBR and SIMV all allowed vasorelaxation against a phenylephrine
CRC, but AICAR does not.
Together these concentration response data conclude that these drugs do cause
vasorelaxation but it may be stimulant dependent. Because concentration response curves look
only at the phasic phase of the response, we were interested if BBR or AICAR would inhibit the
tonic phase of a contraction, which led to the next set of experiments.
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Figure 15: MA Isometric PE CRC. (A) 2mM AICAR (2 hours) showed no effect compared to
vehicle. (B) 30 M A769662 (30 mins) significantly affected the EC50. (C) 10 M BBR (30
mins) significantly (P <0.05) decreased the potency (D) 1, 10 and 30 M SIMV. 30M SIMV
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3.4 Control Force vs. Phosphorylation with 10M PE
There are two phases to mesenteric artery contractions: the initial, quick spike of tension
in the phasic phase, and the tonic phase, where tension fell off early ~ 2 minutes poststimulation, but remained at a pseudo-steady state. Of interest to us was to look at how tension
and phosphorylation of indices of activation (MLC20P & MYPT) changed during 1 dose of
stimulation for an extended time period. A submaximal dose of phenylephrine (m) was
chosen. Time points of 2, 30, and 60 minutes post-stimulation were chosen for time points to
compare to basal.
Active tension, (Fig 16 A) showed that after a contraction was initiated with 10 m PE,
tension was significantly greater compared to basal (P < 0.05) and remained at a pseudo steady
state over the KPSS normalized value of 1 T/To. Myosin light chain phosphorylation (MLC20P),
an indication of activation to generate tension, was measured to determine MA activation. In Fig
16 B, MLC20P increased 2-6 times that over basal and fell off slightly over time, but remained
significantly higher compared to basal, which also could be an indication that the MA is a phasic
artery. In (Fig 16, C) and (Fig 16, D), Myosin phosphatase targeting protein (MYPT)
phosphorylation was measured at two phosphorylation sites. MYPT Threonine 853 (named after
the human sequence) and MYPT Threonine 696. MYPT-T853 (Figure 16, C) significantly
increased at the 2 minute time point, and phosphorylation fell off over time, indicating that
myosin phosphatase is turned back on over time. MYPT-T696 (Fig 16, D) did not change over
time, indicating that myosin phosphatase was never inactivated.
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Figure 16: Rabbit MA. n=4-6 (A) Active tension measurements of MA basal and stimulated
with 10 M PE at three different time points with 2-60’ showing a significant increase in tension
compared to basal (B) Myosin light chain phosphorylation at each time point, MLC20P increased
significantly at 2’ with a small decrease from 2-60’. (C) MYPT-T853 phosphorylation showed a
significant increase at 2’ with a similar trend to MLC20P. (D) MYPT-T696 phosphorylation
showed no change over time.
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3.4 Force and Phosphorylation in the Presence of 30 M BBR
The control data previously mentioned showed that tension and phosphorylation
remained steady between 30 and 60 minutes. Therefore, a test time point of 30 minutes was used.
In figure 17 below, an example force tracing of this data is shown. 30 M BBR (green) clearly
did not allow the PE contraction to be as strong as the control conditions (pink). Therefore, we
looked into the mechanism of BBR and if it was inhibiting phosphorylation of MLC.
Fig 18 A showed the tension data in the presence or absence of 30 M BBR, and in the
presence or absence of 10 M PE. BBR created a tension force ~40% less compared to control
(100%), but there was no difference at basal levels. As expected, the tension increased
significantly with PE for both control and BBR. In Fig 18 B, MLC20P was used as an indication
of activation to generate tension and was measured to determine MA activation. MLC20P was not
different in the presence of BBR compared to DMSO at basal nor stimulated levels, but MLC20P
was increased with PE in both control and BBR compared to basal. Fig 18, C shows that
AMPKp-T172 did not increase at basal levels in the presence of BBR, but AMPKp-T172 did
increase significantly post stimulation. Figure 18 D & E measured MYPT phosphorylation at two
phosphorylation sites. MYPT T-853 (named after the human sequence, myosin regulatory
binding site) and MYPT T-696 (inactivating site). MYPT-T853 increased significantly post
stimulation in both DMSO and BBR, but BBR was not different from vehicle. MYPT-T696 did
not change.
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Figure 17: Example force tracing in the presence of BBR at basal and stimulated levels. 30 M
BBR (green) clearly inhibits a PE induced contraction compared to vehicle (pink).
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Figure 18: Rabbit mesenteric artery. n=4-7. (A) Active tension in the presence of DMSO or 30
M BBR and in the presence or absence of 10 M PE. BBR clearly inhibits tension. (B) Myosin
light chain phosphorylation basal and stimulated ± 30 M BBR. BBR did not significantly
inhibit MLC20P. (C) AMPK-p T172. No significant increases in the presence of 30 M BBR (D)
MYPT-T853 phosphorylation showed an increase after stimulation with PE, but no difference
between control and 30M BBR. (E) MYPT-T696 phosphorylation showed no change.
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3.5 Force and Phosphorylation in the Presence of 2 mM AICAR
These data were the same protocol as BBR mentioned previously. In figure 19 below, an
example force tracing of this data is shown. 2 mM AICAR (green) clearly did not allow the PE
contraction to be as strong as the control conditions (pink), with a significant decrease in tonic
tension. Therefore, we looked into the mechanism of AICAR.
Fig 19 shows the tension tracing in the presence or absence of 2 mM AICAR, and in the
presence or absence of 10 M PE. AICAR created a tension force ~50% less compared to
control, but there was no difference at basal levels. Figure 20 A showed the tension results and
showed that AICAR does inhibit tension due to a PE contraction for 30 minutes. Figure 20 B-D
is preliminary data. In figure 20 B MLC20P appeared decreased post stimulation in the presence
of AICAR. MYPT-T853 (Fig 20 C) appeared increased with PE as expected, and this
phosphorylation appears to decrease in the presence of AICAR. MYPT-T696 (Fig 20 D)
appeared to not change over time, as expected. These data conclude that AICAR does cause
vasorelaxation in a PE induced tonic tension, and that it could possibly inhibit MLC20P.
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Figure 19: Example tension trace in the presence of AICAR at basal and stimulated levels.
AICAR clearly inhibits the tonic portion of a PE contraction.
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Figure 20: Rabbit mesenteric artery, n=1-3. A. 2mM AICAR inhibited active tension compared
to vehicle (DMSO) B. MLC20P appeared decreased in the presence of AICAR. C. MYPT-T853
appeared increased with PE, but decreased in stimulated AICAR. D. MYPT-T696 appeared to
not change.
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3.6 AMPKp-T172 with AMPK Activators
Lastly, and most importantly, was to know if these drugs increased phosphorylation of
AMPK in rabbit mesenteric artery. Figure 21 below is a study with zero load mesenteric arteries
stimulated with AMPK activating drugs, with a control and a positive AMPKp-T172 control
(STARVE, metabolic stress, mentioned in methods) which is thought to activate AMPK directly
through metabolic stress. Interestingly, only 2mM AICAR appeared (P= 0.06) to activate AMPK
in mesenteric artery. These data suggested that even though AICAR, A-769662, BBR and SIMV
can cause vasorelaxation in mesenteric arteries, this effect likely is due to AMPK activation only
for AICAR.
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Figure 21: Rabbit mesenteric artery at Lz. n=3. Starved conditions (PO2 <20 mmHg, no glucose)
used as a positive control. AMPK phosphorylation is not increased by any of the proposed
AMPK activators except AICAR.
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DISCUSSION

Our results showed that AICAR, SIMV and BBR effectively vasorelaxed KCl
contractions (i.e., they inhibited a KCl-induced CRC), but 30 M A769662 did not (see figure
1). Our results showed that AICAR could not vasorelax a PE CRC, but A769662, BBR and
SIMV could (see figure 13). Of importance was that BBR caused relaxation in a PE CRC in both
isometric and isobaric myographs (see figure 13 & 14).
These CRCs focused on the phasic phase of contraction, with concentrations being added
before the phasic force declined to the tonic (maintenance) force. While it was important to
determine if these compounds caused vasorelaxation in mesenteric arteries, it was of interest to
us also to determine if BBR was able to inhibit the tonic portion of a PE induced contraction in
rabbit mesenteric artery.
We measured phosphorylation of indices of activation (MLC20P, MYPT (T853 & T696)
and force in a controlled (i.e., compared to DMSO and basal levels), time sensitive experiment.
Compared to basal, the arteries that were stimulated with a submaximal concentration (10M) of
PE and frozen at time points of 2, 30, and 60 minutes displayed a significant increase in force
compared to basal (see figure 16 A). As expected in a phasic artery, the state of phosphorylation
appeared decreased 2 minutes post-stimulation, but remained at steady state between 30 and 60
minutes (see Figure 16 B). The phosphorylation state of MYPT-T853 (see figure 16 C) (myosin
binding inhibitory site) followed a similar trend with a significant increase in level of
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phosphorylation at 2 minutes and a decrease after 2 minutes, whereas MYPT-T696 displayed no
change over time (see figure 16 D).
Of significant interest to us was to determine if BBR inhibited MLC20P in mesenteric
arteries. We chose a freeze time point of 30 minutes as a result from the control data, and to see
force and phosphorylation during the tonic phase of contraction. These arteries were exposed to
30M BBR or DMSO for 30 minutes prior to stimulation with PE. The arteries were then
stimulated with a submaximal dose of PE (10M) for an additional 30 minutes and frozen. Our
tension data shows that there was no difference basally, but that tension was obviously inhibited
in the presence of BBR + 10M PE (see figure 17). Interestingly, our results show that 30M
BBR did not inhibit MLC20P compared to control (see figure 18 B), nor did it effect any of the
MYPT phosphorylation sites (see figure 18, D & E). Our results also show that AMPK-T172
phosphorylation was increased slightly in the presence of BBR, but not significantly compared to
control (see figure 18 C).
We pretreated mesenteric arteries with 2mM AICAR and stimulated two of the four baths
with 10M PE for an additional 30 minutes (see figure 19). Our results show (see figure 20) that
tonic tension is significantly reduced in the presence of 2mM AICAR. Our preliminary
phosphorylation data showed that AICAR appeared to decrease phosphorylation of MLC20P in
the presence of PE (see figure 20), and decreases phosphorylation of MYPT-T853 in the
presence of PE, with no changes in MYPT-T696.
Lastly, we used zero load mesenteric arteries to measure AMPKp-T172. We used
STARVE conditions (NPSS, no glucose, PO2 <20 mmHg) as a positive control for AMPK
phosphorylation. Our results showed that 2mM AICAR (2 hours) likely increases
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phosphorylation AMPK while 30M A769662, 30M BBR, and 30 M SIMV did not increase
phosphorylation of AMPK in rabbit mesenteric artery (see figure 21).
Our data revealed that these selected drugs caused vasorelaxation in rabbit mesenteric
artery and worked against either KCl or PE CRCs although maybe not to the degree as suggested
in the literature. Even though these drugs did cause vasorelaxation, other unpublished data from
our lab suggests that several of these compounds are Ca2+ channel blockers, and that many of
these drugs have other mechanisms of action other than what is published in the literature.
Although force is decreased in the presence of 30M BBR, it does not significantly inhibit
MLC20P as expected. BBR did not increase phosphorylation of AMPK, therefore, BBR could
have another mechanism for causing vasodilation. Lastly, AICAR caused relaxation in a PE
induced contraction for 30 minutes. This could prove that although AICAR does not work in a
PE CRC, it does work on the tonic phase of a contraction, and could be evidence that CRCs may
not be the appropriate mechanism for determining mechanisms of action of these drugs.
While the data we have for AICAR phosphorylation is preliminary, these findings could
prove that AICAR can cause vasodilation against a PE vasoconstrictor response, but in the tonic
phase of a contraction, not during the phasic phase as studies in our PE CRC’s. This could prove
that CRCs may not be an effective way to determine the effects of drugs on vascular tone.
While vasorelaxation may prove to be beneficial during shock or resuscitation, our
studies reveal that these selected drugs, which have been cited to activate AMPK (Chiou et al,
1991; Goirand F et al, 2007, Hardie DG, 2012; Rossoni, 2011; Sanders MJ, 2007; Sabir and
Bhide, 1971; Steinberg GR, 2009 Sun W, 2006) may cause vasorelaxation in rabbit mesenteric
arteries, but only AICAR was able to increase phosphorylation of AMPK. Further studies into
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the mechanism of 30 M BBR showed that it does not work through AMPK and does not inhibit
MLC20P, therefore the mechanism of BBR is still unclear. Further studies into the mechanism of
AICAR showed that it does work on the tonic portion of a PE contraction, and could prove to be
beneficial in future studies. Compared to other studies in our lab, it seems that AMPKp-T172 in
the presence of the drugs used in these studies can be tissue specific, where these drugs can
increase phosphorylation of AMPK in other arteries but not rabbit MA.
In conclusion, these data revealed that the drugs studied in these experiments may be
effective in causing vasorelaxation, which could be beneficial in a state of shock, but only
AICAR was able to increase phosphorylation of AMPK. Further studies in our lab are being
completed to look into the mechanisms of the drugs that did not increase phosphorylation of
AMPK to determine if they are calcium channel blockers. The preliminary data for AICAR
phosphorylation and tension in tonic force provide a basis for further studies in the lab to
conclude if AICAR would be the selected drug of choice for a hemorrhage/resuscitation
experiment.
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CONCLUSIONS
1. Do these selected AMPK activators cause vasorelaxation?
a. AICAR decreases the efficacy of a KCl CRC but has no effect on a PE CRC
b. A769662 has no effect on a KCl CRC but decreases the potency of a PE CRC
c. BBR: high doses decrease the efficacy of a KCl CRC and decreases the potency
of a PE CRC in isometric and isobaric systems.
2. Do these AMPK activators increase phosphorylation of AMPK-T172?
a. Metabolic stress phosphorylated AMPK in rabbit mesenteric artery.
b. AICAR is the only pharmacological agent used that phosphorylates AMPK in
rabbit mesenteric arteries
3. Does BBR inhibit phosphorylation of MLC20P in rabbit mesenteric arteries?
a. Berberine does not inhibit phosphorylation of MLC20P in Rabbit MA even though
it causes vasorelaxation.
4. AMPK activation may play a vital role in the regulation of smooth muscle during states
of hemorrhagic shock and could prove to be a valuable tool to help reduce incidences of
damage.
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